Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Asklepios BioPharmaceutical
Biotech
BIO, Seaport, Orna and more—Chutes & Ladders
Top BIO lobbyist swiftly departs after BIOSECURE reversal. Karuna leaders launch new venture after BMS buyout. Orna snags top Kite exec as CMO.
Max Bayer
,
Gabrielle Masson
Apr 12, 2024 8:30am
Bayer checks off another early win for gene therapy unit
Jan 4, 2024 9:18am
Bayer's acting BD chief lobbies for the job by making deals
May 24, 2023 3:00am
Hansa touts phase 2 data of one-trick pony transplant therapy
Nov 28, 2022 3:35pm
Bayer-backed AskBio touts early gene therapy data
May 16, 2022 6:00am
To make '1+1=3,' Bayer spends $1.5B for 'undruggables'
Aug 5, 2021 1:30am
